User: Guest  Login
Title:

Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial.

Document type:
journal article
Author(s):
Moe, Sharon M; Chertow, Glenn M; Parfrey, Patrick S; Kubo, Yumi; Block, Geoffrey A; Correa-Rotter, Ricardo; Drüeke, Tilman B; Herzog, Charles A; London, Gerard M; Mahaffey, Kenneth W; Wheeler, David C; Stolina, Maria; Dehmel, Bastian; Goodman, William G; Floege, Jürgen; Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial Investigators*; Santos, J; Najun Zarazaga, C; Marin, I; Garrote, N; Cusumano, A; Peñalba, N; Del Valle, E; Juncos, L; Martinez Saye, J; Lef, L; Al...     »
Abstract:
Patients with kidney disease have disordered bone and mineral metabolism, including elevated serum concentrations of fibroblast growth factor-23 (FGF23). These elevated concentrations are associated with cardiovascular and all-cause mortality. The objective was to determine the effects of the calcimimetic cinacalcet (versus placebo) on reducing serum FGF23 and whether changes in FGF23 are associated with death and cardiovascular events.This was a secondary analysis of a randomized clinical trial...     »
Journal title abbreviation:
Circulation
Year:
2015
Journal volume:
132
Journal issue:
1
Pages contribution:
27-39
Language:
eng
Fulltext / DOI:
doi:10.1161/CIRCULATIONAHA.114.013876
Pubmed ID:
http://view.ncbi.nlm.nih.gov/pubmed/26059012
Print-ISSN:
0009-7322
TUM Institution:
Abteilung für Nephrologie
 BibTeX